|
DK1392714T3
(da)
|
2001-03-12 |
2006-01-09 |
Intercept Pharmaceuticals Inc |
Steroider som agonister for FXR
|
|
WO2005089316A2
(en)
|
2004-03-12 |
2005-09-29 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using fxr ligands
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
DK2040713T3
(da)
|
2006-06-27 |
2014-09-29 |
Intercept Pharmaceuticals Inc |
Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
|
|
CA2928178C
(en)
|
2007-01-19 |
2019-09-10 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US8796249B2
(en)
|
2008-07-30 |
2014-08-05 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
|
HUE039171T2
(hu)
|
2008-11-19 |
2018-12-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulátorok és azok alkalmazási eljárása
|
|
US8318663B2
(en)
|
2008-11-26 |
2012-11-27 |
Satiogen Pharmaceuticals, Inc. |
Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
|
|
EP2367554A4
(en)
|
2008-11-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid reflux inhibitor for the treatment of obesity and diabetes
|
|
WO2010069604A1
(en)
|
2008-12-19 |
2010-06-24 |
Royal College Of Surgeons In Ireland |
Treatment of diarrhoea
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
EP4137137A1
(en)
*
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
ITRM20100329A1
(it)
*
|
2010-06-15 |
2011-12-16 |
Franco Baldelli |
Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
EP2525223A1
(en)
*
|
2011-05-19 |
2012-11-21 |
Universiteit Maastricht |
In vitro method for predicting in vivo genotoxicity of chemical compounds.
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US11154559B2
(en)
|
2011-09-29 |
2021-10-26 |
Ethicon Endo-Surgery, Inc. |
Methods and compositions of bile acids
|
|
JP6217938B2
(ja)
|
2011-10-28 |
2017-10-25 |
ルメナ ファーマシューティカルズ エルエルシー |
小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
|
|
EA038594B1
(ru)
|
2011-10-28 |
2021-09-21 |
Шайр Хьюман Дженетик Терапис, Инк. |
Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
ES2822375T3
(es)
|
2012-06-19 |
2021-04-30 |
Intercept Pharmaceuticals Inc |
Preparación de la forma no cristalina del ácido obeticólico
|
|
NZ707389A
(en)
*
|
2012-10-26 |
2018-08-31 |
Intercept Pharmaceuticals Inc |
Process for preparing bile acid derivatives
|
|
WO2014085474A1
(en)
*
|
2012-11-28 |
2014-06-05 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
|
CN105377870B
(zh)
*
|
2013-05-14 |
2018-04-03 |
英特塞普特医药品公司 |
作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
|
|
CA2914924A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceuticals B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
|
BR112016002268B1
(pt)
*
|
2013-08-01 |
2022-11-01 |
The Penn State Research Foundation |
Uso de inibidores do receptor x farnesoide
|
|
MX377523B
(es)
|
2013-09-11 |
2025-03-10 |
Inst Nat Sante Rech Med |
Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
|
|
MX356006B
(es)
*
|
2013-10-18 |
2018-04-24 |
Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C |
Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
ES2860423T3
(es)
|
2014-05-28 |
2021-10-05 |
Childrens Hospital Med Ct |
Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
|
|
SI3626725T1
(sl)
|
2014-05-29 |
2023-04-28 |
Bar Pharmaceuticals S.R.L. |
Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
|
|
US10238636B2
(en)
|
2014-09-24 |
2019-03-26 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
|
WO2016045480A1
(zh)
*
|
2014-09-28 |
2016-03-31 |
上海源力生物技术有限公司 |
一种奥贝胆酸的制备方法
|
|
CA2963704A1
(en)
|
2014-10-17 |
2016-04-21 |
Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
BR112017009657A2
(pt)
*
|
2014-11-06 |
2018-01-23 |
Enanta Pharmaceuticals, Inc |
análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
|
|
KR102526632B1
(ko)
|
2014-11-19 |
2023-04-27 |
엔제트피 유케이 리미티드 |
스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
|
|
EA033427B1
(ru)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
|
ES2748692T3
(es)
|
2014-11-19 |
2020-03-17 |
Nzp Uk Ltd |
Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
|
|
JP6698085B2
(ja)
|
2014-11-19 |
2020-05-27 |
エヌゼットピー ユーケー リミテッド |
ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
RU2017121457A
(ru)
|
2014-11-26 |
2018-12-26 |
Энанта Фармасьютикалс, Инк. |
Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
|
|
WO2016086115A1
(en)
*
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
|
ES2905872T3
(es)
|
2015-02-06 |
2022-04-12 |
Intercept Pharmaceuticals Inc |
Composiciones farmacéuticas para terapia combinada
|
|
AU2016219266A1
(en)
|
2015-02-11 |
2017-08-10 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
|
RU2712099C2
(ru)
|
2015-03-31 |
2020-01-24 |
Энанта Фармасьютикалс, Инк. |
Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
|
|
CN107613986A
(zh)
|
2015-04-07 |
2018-01-19 |
英特塞普特医药品公司 |
用于组合疗法的药物组合物
|
|
WO2016173493A1
(en)
*
|
2015-04-28 |
2016-11-03 |
Shanghai De Novo Pharmatech Co. Ltd. |
Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
|
|
EP3124080A1
(en)
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
|
AU2016326428A1
(en)
*
|
2015-09-21 |
2018-04-12 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
KR20180052756A
(ko)
|
2015-09-24 |
2018-05-18 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체 제조를 위한 방법 및 중간체
|
|
EP3359160B1
(en)
|
2015-10-07 |
2021-08-25 |
Intercept Pharmaceuticals, Inc. |
Farnesoid x receptor modulators
|
|
IL243707A0
(en)
|
2016-01-20 |
2016-05-01 |
Galmed Res And Dev Ltd |
Treatment to regulate the microbiota in the intestine
|
|
US20200262865A1
(en)
*
|
2016-02-15 |
2020-08-20 |
Alexander Khoruts |
Compositions and methods for treating clostridium associated diseases
|
|
US20170233431A1
(en)
*
|
2016-02-17 |
2017-08-17 |
City Of Hope |
Bile acid derivatives and methods for synthesis and use
|
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
|
MX2018011813A
(es)
|
2016-03-28 |
2019-01-24 |
Intercept Pharmaceuticals Inc |
Medicina obtenida mediante la combinacion de agonista fxr y arb.
|
|
CA3020698A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating or preventing hepatocellular carcinoma
|
|
CN109415685B
(zh)
|
2016-05-05 |
2023-07-04 |
儿童医院医疗中心 |
用于体外制造胃底组织的方法和与其相关的组合物
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
CN109963567A
(zh)
*
|
2016-09-30 |
2019-07-02 |
英特塞普特医药品公司 |
胆汁酸衍生物的结晶形式
|
|
SG10202104575WA
(en)
|
2016-11-04 |
2021-06-29 |
Childrens Hospital Med Ct |
Liver organoid compositions and methods of making and using same
|
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
|
AU2017368069B2
(en)
|
2016-11-29 |
2021-07-08 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonylurea bile acid derivatives
|
|
CA3045145A1
(en)
|
2016-12-05 |
2018-06-14 |
Children's Hospital Medical Center |
Colonic organoids and methods of making and using same
|
|
US10472386B2
(en)
|
2017-02-14 |
2019-11-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR agonists and methods of use thereof
|
|
TW201832768A
(zh)
*
|
2017-03-07 |
2018-09-16 |
英特賽普醫藥品公司 |
治療癌症的方法
|
|
US20180256600A1
(en)
*
|
2017-03-07 |
2018-09-13 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
ES2982801T3
(es)
|
2017-03-28 |
2024-10-17 |
Gilead Sciences Inc |
Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
|
|
JP2020515564A
(ja)
|
2017-03-30 |
2020-05-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
|
|
MX388300B
(es)
|
2017-04-07 |
2025-03-19 |
Enanta Pharm Inc |
Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
|
|
US12281334B2
(en)
|
2017-04-14 |
2025-04-22 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
CA3070837A1
(en)
|
2017-07-24 |
2019-01-31 |
Intercept Pharmaceuticals, Inc. |
Isotopically labeled bile acid derivatives
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
WO2019074793A1
(en)
|
2017-10-10 |
2019-04-18 |
Children's Hospital Medical Center |
OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
|
|
US12379372B2
(en)
|
2017-12-21 |
2025-08-05 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
CA3106634A1
(en)
|
2018-07-26 |
2020-01-30 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
|
US11208571B2
(en)
|
2018-08-08 |
2021-12-28 |
University Of Maryland, College Park |
Methods for nondestructive dispersing of carbon nanomaterials in water
|
|
CN112823012A
(zh)
|
2018-09-12 |
2021-05-18 |
儿童医院医学中心 |
用于产生造血干细胞及其衍生物的类器官组合物
|
|
KR102692309B1
(ko)
|
2019-01-15 |
2024-08-07 |
길리애드 사이언시즈, 인코포레이티드 |
Fxr (nr1h4) 조정 화합물
|
|
WO2020160371A1
(en)
|
2019-02-01 |
2020-08-06 |
The University Of Hong Kong |
Innervated organoid compositions and methods of making same
|
|
WO2020163201A1
(en)
*
|
2019-02-04 |
2020-08-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
|
|
WO2020172075A1
(en)
|
2019-02-19 |
2020-08-27 |
Gilead Sciences, Inc. |
Solid forms of fxr agonists
|
|
US20220226350A1
(en)
|
2019-05-30 |
2022-07-21 |
Intercept Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
|
|
CA3141807A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
US12534709B2
(en)
|
2019-05-31 |
2026-01-27 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
CN112142814B
(zh)
*
|
2019-06-26 |
2021-09-28 |
江苏吉贝尔药业股份有限公司 |
牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
|
|
WO2021009332A1
(en)
|
2019-07-18 |
2021-01-21 |
Enyo Pharma |
Method for decreasing adverse-effects of interferon
|
|
IL293892A
(en)
|
2020-01-15 |
2022-08-01 |
Inserm Institut National De La Sant? Et De La Rech M?Dicale |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
MX2023008365A
(es)
|
2021-01-14 |
2023-10-04 |
Enyo Pharma |
Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
|
|
TW202308629A
(zh)
|
2021-04-28 |
2023-03-01 |
法商Ｅｎｙｏ製藥公司 |
使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
|
|
CN119950519B
(zh)
*
|
2025-01-07 |
2025-11-21 |
山东省海洋科学研究院(青岛国家海洋科学研究中心) |
奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用
|